Vir Biotechnology, Inc. (VIR)
Automate Your Wheel Strategy on VIR
With Tiblio's Option Bot, you can configure your own wheel strategy including VIR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VIR
- Rev/Share 0.1427
- Book/Share 7.5931
- PB 0.6954
- Debt/Equity 0.0921
- CurrentRatio 6.7903
- ROIC -0.5119
- MktCap 729896640.0
- FreeCF/Share -3.0708
- PFCF -1.7291
- PE -1.2565
- Debt/Assets 0.0735
- DivYield 0
- ROE -0.4746
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study
Published: May 09, 2025 by: Business Wire
Sentiment: Neutral
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced 24-week post-end of treatment data from Part B of the ongoing MARCH Phase 2 clinical study evaluating tobevibart and elebsiran without or with pegylated interferon alpha (PEG-IFNα) in participants with chronic hepatitis B (CHB). The study-defined primary endpoint, proportion of participants with undetectable hepatitis B surface antigen (HBsAg) at 24 weeks post-end of treatment, was achieved by 17% (3/18) and 2.
Read More
Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Positive
Vir Biotechnology, Inc.'s phase 3 ECLIPSE program for HDV, leveraging tobevibart and elebsiran, shows promise based on positive phase 2 SOLSTICE study results. The global hepatitis D market size is projected to surpass $1.05 billion by 2034. VIR-5518 and VIR-5500 are dual-masked HER2 and PSMA T-cell engagers being developed to target solid tumors; The current status of these candidates is that dose-escalation for both are ongoing.
Read More
Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Richard Lepke - Senior Director, Investor Relations Marianne De Backer - Chief Executive Officer Mark Eisner - Executive Vice President & Chief Medical Officer Jason O'Byrne - Executive Vice President & Chief Financial Officer Mika Derynck - Executive Vice President of Therapeutic Head Oncology Conference Call Participants Gena Wang - Barclays Paul Choi - Goldman Sachs Nick Gasic - Leerink Partners Phil Nadeau - TD Cowen Patrick Trucchio - H.C. Wainwright & Co. Joseph Stringer - Needham & Company Operator Hello.
Read More
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.48 per share a year ago.
Read More
Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025
Published: April 24, 2025 by: Business Wire
Sentiment: Neutral
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from a 24-week subgroup analysis of its ongoing Phase 2 SOLSTICE trial in chronic hepatitis delta at the upcoming European Association for the Study of the Liver (EASL) Congress 2025 in Amsterdam (The Netherlands), May 7-10. The Company will also present 24 Week post-treatment follow-up data from the MARCH Phase 2 clinical study evaluating combinations of tobevibart and elebsiran,.
Read More
Vir Biotechnology, Inc. (VIR) Q4 2024 Earnings Call Transcript
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Richard Lepke - Senior Director, Investor Relations Marianne De Backer - Chief Executive Officer Mark Eisner - Executive Vice President & Chief Medical Officer Jason O'Byrne - Executive Vice President & Chief Financial Officer Mika Derynck - Executive Vice President of Therapeutic Head Oncology Conference Call Participants Hang Hu - Barclays Paul Choi - Goldman Sachs Phil Nadeau - TD Cowen Alec Stranahan - Bank of America Joseph Stringer - Needham Patrick Trucchio - H.C. Wainwright & Co. Operator Hello.
Read More
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Lags Revenue Estimates
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Negative
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.86 per share a year ago.
Read More
About Vir Biotechnology, Inc. (VIR)
- IPO Date 2019-10-11
- Website https://www.vir.bio
- Industry Biotechnology
- CEO Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.
- Employees 408